A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection

Stephen C. Piscitelli, Niranjan Bhat, Alice Pau

Research output: Contribution to journalArticle

Abstract

Immunomodulation has become a major focus of HIV research in an effort to augment, boost or restore the patient's damaged immune system. Recombinant interleukin-2 is currently being studied in phase II/III trials in HIV-infected patients. Several clinical studies have demonstrated that intermittent regimens are associated with marked rises in CD4+ cell counts without an increase in viral load. Most of these studies employ 5 consecutive days of interleukin-2 therapy by continuous intravenous infusion or subcutaneous injection, repeated every 8 weeks. An alternative strategy is the daily administration of low doses of interleukin-2, but clinical experience with this regimen is limited. Interleukin-2 administration can adversely affect virtually every organ system, requiring aggressive supportive care. A variety of administration strategies and interventions are being evaluated to minimise toxicity. Currently, no clinical end-point data are available for interleukin-2 in HIV-infected patients. Until phase III studies are completed, interleukin-2 can be used in the research setting as an immunomodulator and adjunct to antiretroviral therapy. Its potential to activate latently infected cells and promote HIV eradication from reservoir sites is also an important area for further study. If clinical benefit can be demonstrated, interleukin-2 could be useful as an adjunct to antiretroviral therapy if adverse effects can be minimised and therapy can be given infrequently on an outpatient basis.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalDrug Safety
Volume22
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

HIV Infections
Interleukin-2
Antiviral Agents
HIV
Therapeutics
Immunomodulation
Immune system
Immunologic Factors
Subcutaneous Injections
CD4 Lymphocyte Count
Viral Load
Research
Intravenous Infusions
Intravenous Injections
Toxicity
Immune System
Outpatients

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection. / Piscitelli, Stephen C.; Bhat, Niranjan; Pau, Alice.

In: Drug Safety, Vol. 22, No. 1, 2000, p. 19-31.

Research output: Contribution to journalArticle

Piscitelli, SC, Bhat, N & Pau, A 2000, 'A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection', Drug Safety, vol. 22, no. 1, pp. 19-31.
Piscitelli, Stephen C. ; Bhat, Niranjan ; Pau, Alice. / A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection. In: Drug Safety. 2000 ; Vol. 22, No. 1. pp. 19-31.
@article{5e8e4f78906944fca64ac3daed4539af,
title = "A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection",
abstract = "Immunomodulation has become a major focus of HIV research in an effort to augment, boost or restore the patient's damaged immune system. Recombinant interleukin-2 is currently being studied in phase II/III trials in HIV-infected patients. Several clinical studies have demonstrated that intermittent regimens are associated with marked rises in CD4+ cell counts without an increase in viral load. Most of these studies employ 5 consecutive days of interleukin-2 therapy by continuous intravenous infusion or subcutaneous injection, repeated every 8 weeks. An alternative strategy is the daily administration of low doses of interleukin-2, but clinical experience with this regimen is limited. Interleukin-2 administration can adversely affect virtually every organ system, requiring aggressive supportive care. A variety of administration strategies and interventions are being evaluated to minimise toxicity. Currently, no clinical end-point data are available for interleukin-2 in HIV-infected patients. Until phase III studies are completed, interleukin-2 can be used in the research setting as an immunomodulator and adjunct to antiretroviral therapy. Its potential to activate latently infected cells and promote HIV eradication from reservoir sites is also an important area for further study. If clinical benefit can be demonstrated, interleukin-2 could be useful as an adjunct to antiretroviral therapy if adverse effects can be minimised and therapy can be given infrequently on an outpatient basis.",
author = "Piscitelli, {Stephen C.} and Niranjan Bhat and Alice Pau",
year = "2000",
language = "English (US)",
volume = "22",
pages = "19--31",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection

AU - Piscitelli, Stephen C.

AU - Bhat, Niranjan

AU - Pau, Alice

PY - 2000

Y1 - 2000

N2 - Immunomodulation has become a major focus of HIV research in an effort to augment, boost or restore the patient's damaged immune system. Recombinant interleukin-2 is currently being studied in phase II/III trials in HIV-infected patients. Several clinical studies have demonstrated that intermittent regimens are associated with marked rises in CD4+ cell counts without an increase in viral load. Most of these studies employ 5 consecutive days of interleukin-2 therapy by continuous intravenous infusion or subcutaneous injection, repeated every 8 weeks. An alternative strategy is the daily administration of low doses of interleukin-2, but clinical experience with this regimen is limited. Interleukin-2 administration can adversely affect virtually every organ system, requiring aggressive supportive care. A variety of administration strategies and interventions are being evaluated to minimise toxicity. Currently, no clinical end-point data are available for interleukin-2 in HIV-infected patients. Until phase III studies are completed, interleukin-2 can be used in the research setting as an immunomodulator and adjunct to antiretroviral therapy. Its potential to activate latently infected cells and promote HIV eradication from reservoir sites is also an important area for further study. If clinical benefit can be demonstrated, interleukin-2 could be useful as an adjunct to antiretroviral therapy if adverse effects can be minimised and therapy can be given infrequently on an outpatient basis.

AB - Immunomodulation has become a major focus of HIV research in an effort to augment, boost or restore the patient's damaged immune system. Recombinant interleukin-2 is currently being studied in phase II/III trials in HIV-infected patients. Several clinical studies have demonstrated that intermittent regimens are associated with marked rises in CD4+ cell counts without an increase in viral load. Most of these studies employ 5 consecutive days of interleukin-2 therapy by continuous intravenous infusion or subcutaneous injection, repeated every 8 weeks. An alternative strategy is the daily administration of low doses of interleukin-2, but clinical experience with this regimen is limited. Interleukin-2 administration can adversely affect virtually every organ system, requiring aggressive supportive care. A variety of administration strategies and interventions are being evaluated to minimise toxicity. Currently, no clinical end-point data are available for interleukin-2 in HIV-infected patients. Until phase III studies are completed, interleukin-2 can be used in the research setting as an immunomodulator and adjunct to antiretroviral therapy. Its potential to activate latently infected cells and promote HIV eradication from reservoir sites is also an important area for further study. If clinical benefit can be demonstrated, interleukin-2 could be useful as an adjunct to antiretroviral therapy if adverse effects can be minimised and therapy can be given infrequently on an outpatient basis.

UR - http://www.scopus.com/inward/record.url?scp=0033965995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033965995&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 19

EP - 31

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 1

ER -